AbbVie obtained exclusive rights in North America, Europe, Japan, and Greater China to ISB 2001, a first-in-class CD38 x BCMA x CD3 trispecific antibody for R/R multiple myeloma, from Glenmark subsidiary IGI. Upfront $700M and up to $1.225B in milestones plus tiered royalties. Total ~$1.925B.